ABT · News · 20261105N
Licensing / Collaboration Deals
ABBOTT LABORATORIES · 2026-11-05 · Importance 31 · Surprise 42
Abbott and Novo expanded their strategic collaboration on November 5, 2026, to launch Plosbrio (semaglutide) in Singapore and other Asia Pacific countries. Plosbrio is described as a second brand of Novo’s Ozempic for adults with type 2 diabetes. The announcement cited Abbott’s regional healthcare footprint and diabetes-care expertise as part of the collaboration, but reported no deal value, revenue forecast, or other financial terms.